{"id":60897,"date":"2026-03-24T13:47:58","date_gmt":"2026-03-24T05:47:58","guid":{"rendered":"https:\/\/flcube.com\/?p=60897"},"modified":"2026-03-24T13:47:58","modified_gmt":"2026-03-24T05:47:58","slug":"innovents-ibi302-hits-star-trial-primary-endpoint-dual-vegf-complement-inhibitor-shows-16-week-dosing-and-50-macular-atrophy-reduction-in-namd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60897","title":{"rendered":"Innovent&#8217;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD"},"content":{"rendered":"\n<p><strong>Innovent Biologics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>) announced that its <strong>Phase III STAR study<\/strong> (NCT05972473) evaluating <strong>efdamrofusp alfa (IBI302)<\/strong> in <strong>Chinese patients with neovascular age\u2011related macular degeneration (nAMD)<\/strong> met its <strong>primary endpoint at 52 weeks<\/strong>, demonstrating <strong>non\u2011inferior visual acuity improvement<\/strong> vs. <strong>aflibercept<\/strong> (Eylea\u00ae) with <strong>ultra\u2011long 16\u2011week dosing intervals<\/strong> and a <strong>~50% reduction in macular atrophy (MA)<\/strong> \u2013 a potential <strong>best\u2011in\u2011class<\/strong> profile for the novel <strong>VEGF\/complement dual\u2011target therapy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone-star-phase-iii\">Clinical Milestone \u2013 STAR Phase III<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>STAR (NCT05972473) \u2013 Phase III<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Efdamrofusp alfa (IBI302)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Innovent Biologics, Inc. (HKG: 1801)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neovascular age\u2011related macular degeneration (nAMD)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Chinese subjects (n=<strong>600<\/strong> enrolled)<\/td><\/tr><tr><td><strong>Dose<\/strong><\/td><td><strong>8 mg<\/strong> IBI302 vs. <strong>2 mg<\/strong> aflibercept<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Visual acuity improvement \u2013 <strong>non\u2011inferior to aflibercept<\/strong><\/td><\/tr><tr><td><strong>Result<\/strong><\/td><td><strong>Met<\/strong> \u2013 8 mg IBI302 non\u2011inferior to 2 mg aflibercept<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-secondary-endpoints-differentiation-profile\">Key Secondary Endpoints \u2013 Differentiation Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>IBI302 Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Dosing Interval Achievement<\/strong><\/td><td><strong>86%<\/strong> achieved \u226512 weeks; <strong>72.8%<\/strong> achieved Q16W (16\u2011week interval)<\/td><td><strong>Ultra\u2011long dosing<\/strong> reduces injection burden vs. standard Q8W aflibercept; potential competitive advantage in patient compliance<\/td><\/tr><tr><td><strong>Macular Atrophy (MA) Reduction<\/strong><\/td><td><strong>~50% reduction<\/strong> vs. aflibercept group<\/td><td><strong>Anatomical benefit<\/strong> \u2013 MA associated with long\u2011term vision loss; potential disease\u2011modifying effect<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Overall favorable<\/td><td>Supports outpatient intravitreal administration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-dual-target-innovation\">Mechanism of Action \u2013 Dual\u2011Target Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>IBI302<\/strong> \u2013 <strong>recombinant VEGFR\/CR1 fusion protein<\/strong><\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong><\/li>\n\n\n\n<li><strong>VEGF pathway inhibition<\/strong> \u2013 blocks VEGF\u2011mediated angiogenesis (standard anti\u2011VEGF mechanism)<\/li>\n\n\n\n<li><strong>Complement pathway inhibition<\/strong> \u2013 blocks complement activation via <strong>CR1 (complement receptor 1)<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Hypothesis:<\/strong><\/li>\n\n\n\n<li>Complement activation implicated in <strong>macular atrophy pathogenesis<\/strong><\/li>\n\n\n\n<li>Dual inhibition addresses <strong>both neovascularization and retinal degeneration<\/strong><\/li>\n\n\n\n<li>Potential for <strong>disease\u2011modifying<\/strong> benefit beyond symptom control<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-positioning\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>nAMD Treatment Landscape<\/th><th>IBI302 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Standard of Care<\/strong><\/td><td>Anti\u2011VEGF monotherapy (aflibercept Q8W, ranibizumab, bevacizumab)<\/td><td>Non\u2011inferior efficacy + <strong>extended dosing<\/strong> + <strong>anatomical benefit<\/strong><\/td><\/tr><tr><td><strong>Long\u2011Acting Competition<\/strong><\/td><td>Eylea HD (8 mg aflibercept, Q12\u201116W); Vabysmo (faricimab, Q16W)<\/td><td>IBI302 matches Q16W interval with <strong>complement differentiation<\/strong><\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Macular atrophy (affects 30\u201140% of long\u2011term anti\u2011VEGF users); injection fatigue<\/td><td><strong>50% MA reduction<\/strong> + <strong>16\u2011week dosing<\/strong> addresses both issues<\/td><\/tr><tr><td><strong>China Market Dynamics<\/strong><\/td><td>~3 million nAMD patients; anti\u2011VEGF penetration &lt;20%; growing biologics access<\/td><td>China\u2011origin asset supports pricing flexibility and NRDL inclusion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>nAMD Market Dynamics:<\/strong> Global nAMD therapeutics <strong>US$15+ billion<\/strong> annually; China <strong>RMB8\u201110 billion<\/strong> with 15\u201120% growth; long\u2011acting therapies (Eylea HD, Vabysmo) capturing 40%+ share due to reduced injection burden; IBI302&#8217;s <strong>dual\u2011mechanism differentiation<\/strong> positions for premium segment.<\/li>\n\n\n\n<li><strong>Innovent Ophthalmology Strategy:<\/strong> IBI302 lead asset in <strong>ophthalmology franchise<\/strong>; STAR success validates <strong>fusion protein platform<\/strong>; pipeline includes <strong>IBI333 (VEGF\/ANG2 bispecific)<\/strong> for diabetic macular edema; potential for <strong>integrated retina portfolio<\/strong> vs. single\u2011asset competitors.<\/li>\n\n\n\n<li><strong>Regulatory &amp; Commercial Timeline:<\/strong> NDA submission to NMPA <strong>Q2\u2011Q3 2026<\/strong>; potential China approval <strong>H2 2027<\/strong>; ex\u2011China rights licensing opportunity (US\/EU) with estimated deal value <strong>US$500 million\u20111 billion<\/strong> upon Phase III data disclosure; global Phase III (non\u2011Chinese populations) likely required for US FDA submission.<\/li>\n\n\n\n<li><strong>Competitive Differentiation vs. Vabysmo:<\/strong> Roche&#8217;s faricimab (VEGF\/ANG2 bispecific) offers Q16W dosing but <strong>no complement mechanism<\/strong>; IBI302&#8217;s <strong>MA reduction benefit<\/strong> (50% vs. aflibercept) suggests <strong>superior anatomical outcome<\/strong> potential; head\u2011to\u2011head study vs. Vabysmo would establish market positioning.<\/li>\n\n\n\n<li><strong>Pricing &amp; Access Strategy:<\/strong> Assuming NRDL inclusion at <strong>RMB8,000\u201112,000 per injection<\/strong> (vs. Eylea HD ~RMB15,000); 16\u2011week interval reduces annual cost vs. Q8W therapies; <strong>MA reduction claim<\/strong> supports premium positioning and physician preference in long\u2011term therapy selection.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory submission timelines, commercialization expectations, and competitive positioning for efdamrofusp alfa (IBI302). Actual results may differ due to NMPA review outcomes, competitive dynamics with Eylea HD and Vabysmo, and manufacturing scale\u2011up for fusion protein production.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,910,198],"class_list":["post-60897","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent&#039;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age\u2011related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non\u2011inferior visual acuity improvement vs. aflibercept (Eylea\u00ae) with ultra\u2011long 16\u2011week dosing intervals and a ~50% reduction in macular atrophy (MA) \u2013 a potential best\u2011in\u2011class profile for the novel VEGF\/complement dual\u2011target therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60897\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent&#039;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age\u2011related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non\u2011inferior visual acuity improvement vs. aflibercept (Eylea\u00ae) with ultra\u2011long 16\u2011week dosing intervals and a ~50% reduction in macular atrophy (MA) \u2013 a potential best\u2011in\u2011class profile for the novel VEGF\/complement dual\u2011target therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60897\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T05:47:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60897#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60897\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent&#8217;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\\\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD\",\"datePublished\":\"2026-03-24T05:47:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60897\"},\"wordCount\":613,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60897#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60897\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60897\",\"name\":\"Innovent's IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\\\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-24T05:47:58+00:00\",\"description\":\"Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age\u2011related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non\u2011inferior visual acuity improvement vs. aflibercept (Eylea\u00ae) with ultra\u2011long 16\u2011week dosing intervals and a ~50% reduction in macular atrophy (MA) \u2013 a potential best\u2011in\u2011class profile for the novel VEGF\\\/complement dual\u2011target therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60897#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60897\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60897#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent&#8217;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\\\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent's IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age\u2011related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non\u2011inferior visual acuity improvement vs. aflibercept (Eylea\u00ae) with ultra\u2011long 16\u2011week dosing intervals and a ~50% reduction in macular atrophy (MA) \u2013 a potential best\u2011in\u2011class profile for the novel VEGF\/complement dual\u2011target therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60897","og_locale":"en_US","og_type":"article","og_title":"Innovent's IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD","og_description":"Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age\u2011related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non\u2011inferior visual acuity improvement vs. aflibercept (Eylea\u00ae) with ultra\u2011long 16\u2011week dosing intervals and a ~50% reduction in macular atrophy (MA) \u2013 a potential best\u2011in\u2011class profile for the novel VEGF\/complement dual\u2011target therapy.","og_url":"https:\/\/flcube.com\/?p=60897","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-24T05:47:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60897#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60897"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent&#8217;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD","datePublished":"2026-03-24T05:47:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60897"},"wordCount":613,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 1801","Innovent Biologics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60897#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60897","url":"https:\/\/flcube.com\/?p=60897","name":"Innovent's IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-24T05:47:58+00:00","description":"Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age\u2011related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non\u2011inferior visual acuity improvement vs. aflibercept (Eylea\u00ae) with ultra\u2011long 16\u2011week dosing intervals and a ~50% reduction in macular atrophy (MA) \u2013 a potential best\u2011in\u2011class profile for the novel VEGF\/complement dual\u2011target therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60897#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60897"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60897#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent&#8217;s IBI302 Hits STAR Trial Primary Endpoint \u2013 Dual VEGF\/Complement Inhibitor Shows 16\u2011Week Dosing and 50% Macular Atrophy Reduction in nAMD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60897"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60897\/revisions"}],"predecessor-version":[{"id":60898,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60897\/revisions\/60898"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}